Shares of Agios Pharmaceuticals (NASDAQ:AGIO) advanced to $51.97. The price had gained 3.23% or 1.63 points intraday. The latest trading session witnessed $42.46 million in upticks and $45.48 million in downticks, resulting in net money flow of (-3.02) million. The up/down ratio for the day stood at 0.93. On a weekly scale, the price has seen a change of -8.5%. From the trading data available, it was disclosed that a block trade of negative money flow worth $(-0.63) million occurred during the day. $1.99 million in uptick and $2.62 million in downtick were the highlight of the block transaction which had an up/down ratio of 0.76.
Currently the company Insiders own 14.67% of Agios Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.89% . Institutional Investors own 88.79% of Agios Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -8.5%. On the companys insider trading activities, The officer (Chief Scientific Officer), of Agios Pharmaceuticals Inc, Biller Scott had unloaded 27,500 shares at $65 per share in a transaction on June 8, 2016. The total value of transaction was $1,787,500. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Agios Pharmaceuticals (NASDAQ:AGIO) : On Monday heightened volatility was witnessed in Agios Pharmaceuticals (NASDAQ:AGIO) which led to swings in the share price. The stock opened for trading at $54.56 and hit $54.68 on the upside , eventually ending the session at $51.97, with a gain of 3.23% or 1.625 points. The heightened volatility saw the trading volume jump to 3,021,678 shares. The 52-week high of the share price is $120.96 and the company has a market cap of $1,971 million. The 52-week low of the share price is at $33.5 .
Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Credit Suisse maintains its rating on Agios Pharmaceuticals (NASDAQ:AGIO). The rating major has initiated the coverage with outperform rating on the shares. The Analysts at Credit Suisse raises the price target from $65 per share to $70 per share. The rating by the firm was issued on May 18, 2016.
Agios Pharmaceuticals, Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221, AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.